2.44
price down icon0.41%   -0.01
after-market 시간 외 거래: 2.37 -0.07 -2.87%
loading
전일 마감가:
$2.45
열려 있는:
$2.41
하루 거래량:
6,676
Relative Volume:
0.20
시가총액:
$6.94M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-2.4158
EPS:
-1.01
순현금흐름:
$-24.23M
1주 성능:
-6.87%
1개월 성능:
+3.39%
6개월 성능:
-51.39%
1년 성능:
-68.17%
1일 변동 폭
Value
$2.37
$2.4629
1주일 범위
Value
$2.36
$2.6576
52주 변동 폭
Value
$2.115
$15.75

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
명칭
Moleculin Biotech Inc
Name
전화
713-300-5160
Name
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
직원
18
Name
트위터
@moleculinbio
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
MBRX's Discussions on Twitter

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-07-18 재개 Oppenheimer Outperform

Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스

pulisher
09:56 AM

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - Longview News-Journal

09:56 AM
pulisher
08:23 AM

Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com - Defense World

08:23 AM
pulisher
Nov 04, 2024

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin - Star Local Media

Nov 04, 2024
pulisher
Oct 30, 2024

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML - GuruFocus.com

Oct 30, 2024
pulisher
Oct 28, 2024

Soft Tissue Sarcoma Market Growth to Accelerate in Forecast - openPR

Oct 28, 2024
pulisher
Oct 28, 2024

Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com - Defense World

Oct 28, 2024
pulisher
Oct 26, 2024

Moleculin Biotech stockholders approve new stock plan By Investing.com - Investing.com South Africa

Oct 26, 2024
pulisher
Oct 26, 2024

Moleculin to Participate in the Virtual Investor Lunch Break: Th - GuruFocus.com

Oct 26, 2024
pulisher
Oct 26, 2024

Moleculin Abstract Accepted for Poster Presentation at the Europ - GuruFocus.com

Oct 26, 2024
pulisher
Oct 25, 2024

Moleculin Biotech stockholders approve new stock plan - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Moleculin Biotech’s Annual Meeting Decisions and Elections - TipRanks

Oct 25, 2024
pulisher
Oct 19, 2024

Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

Moleculin Biotech Highlights Annamycin’s AML Treatment Potential - Yahoo Finance

Oct 18, 2024
pulisher
Oct 17, 2024

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available - Financial Times

Oct 17, 2024
pulisher
Oct 14, 2024

Ependymoma Market to Rise by 2032, DelveInsight | Fera - openPR

Oct 14, 2024
pulisher
Oct 12, 2024

StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World

Oct 12, 2024
pulisher
Oct 09, 2024

Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: P - GuruFocus.com

Oct 09, 2024
pulisher
Oct 07, 2024

Moleculin Announces Proposed Underwritten Public Offering - Marketscreener.com

Oct 07, 2024
pulisher
Oct 07, 2024

Moleculin Announces Full Exercise of Over-Allotment Option - Marketscreener.com

Oct 07, 2024
pulisher
Oct 07, 2024

Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 - Marketscreener.com

Oct 07, 2024
pulisher
Oct 04, 2024

Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Moleculin to Present at Two Upcoming Investor Conferences - Marketscreener.com

Oct 04, 2024
pulisher
Oct 04, 2024

Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com - Defense World

Oct 04, 2024
pulisher
Oct 02, 2024

Moleculin Biotech Releases Updated Corporate Presentation - TipRanks

Oct 02, 2024
pulisher
Sep 26, 2024

Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com - Defense World

Sep 26, 2024
pulisher
Sep 23, 2024

Moleculin Biotech Shares Rise 12% After Positive Annamycin Data - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Moleculin Biotech Sees Positive Data From Annamycin Study - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Moleculin Biotech’s Annamycin Shows Promise in Cancer Treatment - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma - PR Newswire

Sep 23, 2024
pulisher
Sep 19, 2024

Kendall Capital Management Buys 305 Shares of McKesson Co. (NYSE:MCK) - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Playstudios CFO sells $39,500 in stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Mitcham shares upgraded to outperform on value after preferred conversion - Investing.com India

Sep 18, 2024
pulisher
Sep 17, 2024

Medipharm Labs Shares Jump on Clearing Remaining Debt - MarketWatch

Sep 17, 2024
pulisher
Sep 17, 2024

MediPharm Labs Announces $2.1M Debt Repayment - Financial Times

Sep 17, 2024
pulisher
Sep 16, 2024

Moleculin Biotech CEO Discusses Clinical Trials and Drug Development - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

Moleculin Biotech Shares Insights in Corporate Update - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

Moleculin Participates in Virtual Investor "What this Means" Segment - PR Newswire

Sep 16, 2024
pulisher
Sep 16, 2024

Moleculin Participates in Virtual Investor "What this Means" Segment – Company Announcement - Financial Times

Sep 16, 2024
pulisher
Sep 10, 2024

Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com - Defense World

Sep 10, 2024
pulisher
Sep 09, 2024

Moleculin Biotech Advances Phase 2 Glioblastoma Study - TipRanks

Sep 09, 2024
pulisher
Sep 09, 2024

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma - Marketscreener.com

Sep 09, 2024
pulisher
Sep 03, 2024

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StreetInsider.com

Sep 03, 2024
pulisher
Aug 26, 2024

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - PR Newswire

Aug 26, 2024
pulisher
Aug 19, 2024

Moleculin Biotech Raises Capital with Public Offering - TipRanks

Aug 19, 2024
pulisher
Aug 19, 2024

Moleculin Announces Closing of up to $16.5 Million Public Offering - Financial Times

Aug 19, 2024
pulisher
Aug 19, 2024

Q3 2024 EPS Estimates for Moleculin Biotech, Inc. (NASDAQ:MBRX) Cut by Analyst - Defense World

Aug 19, 2024
pulisher
Aug 17, 2024

Moleculin Biotech (NASDAQ:MBRX) Stock Passes Below Fifty Day Moving Average of $3.45 - Defense World

Aug 17, 2024
pulisher
Aug 16, 2024

Moleculin Biotech Secures Funding for Drug Development Programs - TipRanks

Aug 16, 2024
pulisher
Aug 16, 2024

Moleculin Prices of up to $16.5 Million Public Offering - citybiz

Aug 16, 2024

Moleculin Biotech Inc (MBRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Moleculin Biotech Inc 주식 (MBRX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
George Robert E.
Director
Dec 26 '23
Buy
0.69
14,493
10,000
14,660
KLEMP WALTER V
CEO and President
Dec 26 '23
Buy
0.69
188,404
129,999
680,880
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):